510(k) · Cleared
ClearedStatusfirst CHF (Congestive Heart Failure) NT-Probnp, Model 20204
Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly
Nanogen, Inc. · NBC Test, Natriuretic Peptide
Cleared on Mar 13, 2006 as substantially equivalent to K032646 (Roche Diagnostics Corp., 2003) after a 270-day review. Its family tree reaches back 3 generations to 2000. 1 later device descends from it.
- Decided
- Mar 13, 2006
- Review
- 270 days
- Class
- Class II
- Product code
- NBC
- Recalls
- None
- Predicates
- 1
Its longest line of descent runs back 3 generations to DEN000010 (2000). 1 later device descends from it, 1 citing it directly.
- Root · 3 generations backDEN000010 Triage B-Type Natriuretic Peptide (BNP) TestBiosite Incorporated · 2000
- 2 generations backK022516 Elecsys Probnp ImmunoassayRoche Diagnostics Corp. · 2002
- 1 generation backK032646 Elecsys Probnp ImmunoassayRoche Diagnostics Corp. · 2003
- This deviceK051596 Statusfirst CHF (Congestive Heart Failure) NT-Probnp, Model 20204Nanogen, Inc. · 2006
- Descendant · cites it directly · 0 of its ownK063662 Ramp NT-Probnp AssayResponse Biomedical Corp. · 2008
Most influential descendants
Showing 1 of 1 · See all- K063662Ramp NT-Probnp AssayResponse Biomedical Corp. · 2008 · cites it directly0descendants
View FIG. 1 as a table
Line of descent and top descendants
| Generation | Number | Device | Applicant | Decided | Recalls |
|---|---|---|---|---|---|
| −3 | DEN000010 | Triage B-Type Natriuretic Peptide (BNP) Test | Biosite Incorporated | 2000 | — |
| −2 | K022516 | Elecsys Probnp Immunoassay | Roche Diagnostics Corp. | 2002 | — |
| −1 | K032646 | Elecsys Probnp Immunoassay | Roche Diagnostics Corp. | 2003 | — |
| 0 (this device) | K051596 | Statusfirst CHF (Congestive Heart Failure) NT-Probnp, Model 20204 | Nanogen, Inc. | 2006 | — |
| +1 | K063662 | Ramp NT-Probnp Assay | Response Biomedical Corp. | 2008 | — |
Descendants by year cleared
| Year cleared | Devices | With a Class I recall |
|---|---|---|
| 2008 | 1 | 0 |
Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.
Planning a device in NBC? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.
Top candidate predicates for a new NBC device
- #1 K262109 Access NT-proBNPscore 13.8 · 7 generations · no Class I recall
- #2 Held for the reportin the report
- #3 Held for the reportin the report
What was it cleared against? (1)
Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.
| Type | Number | Device | Decided |
|---|---|---|---|
| * | K032646 | Elecsys Probnp ImmunoassaySummary page 1…system (21 CFR 862.1117, product code NBC) Predicate Device Roche's Elecsys® pro-BNP Immunoassay K032646 Intended Use StatusFirstTm CHF (Congestive Heart Failure) NT- proBNP is a rapid t… | 2003 |
What descends from it? (1)
1 later device cites it directly; ranked here by how many devices descend from each in turn.
| Number | Device | Decided | Descendants |
|---|---|---|---|
| K063662 | Ramp NT-Probnp Assay | 2008 | 0 |
Has anything in its family been recalled? (0 Class I)
No FDA recall names this device.
No ancestor or descendant has a Class I recall.
What does this lineage say?
- The line of descent spans 6 years and passes through 3 companies; a new generation was cleared every 2.0 years on median.
- None of the 3 ancestors has a recall.
- Of its descendants, K063662 (Response Biomedical Corp., 2008) has gone furthest, with 0 descendants of its own.
- 7 other devices also cite its predicate K032646.
How does its category compare?
All NBC devicesNBC Test, Natriuretic Peptide: FDA decisions, review times, recalls and adverse event reports over 20 years.
FDA decisions per year · NBC
1in 2025
2026 to Oct 25, outlined.
Median 510(k) review, days · NBC
126in 2008
Receipt to decision; years with fewer than 3 clearances left blank.
Recalls per year · NBC
1in 2020
Class I (0 since 2007) Class II/III not classified
Adverse event reports per year · NBC
17in 2025
MAUDE reports naming product code NBC, not matched to any one device; reports are not rates.
View these four charts as a table
| Year | Decisions | Median 510(k) review, days | Recalls (Class I) | MAUDE reports |
|---|---|---|---|---|
| 2007 | 2 | — | 0 | 17 |
| 2008 | 7 | 126 | 0 | 15 |
| 2009 | 0 | — | 0 | 35 |
| 2010 | 1 | — | 1 | 61 |
| 2011 | 0 | — | 0 | 53 |
| 2012 | 0 | — | 2 | 23 |
| 2013 | 0 | — | 0 | 13 |
| 2014 | 0 | — | 1 | 70 |
| 2015 | 0 | — | 1 | 43 |
| 2016 | 0 | — | 0 | 31 |
| 2017 | 0 | — | 0 | 9 |
| 2018 | 0 | — | 1 | 7 |
| 2019 | 0 | — | 0 | 9 |
| 2020 | 1 | — | 1 | 6 |
| 2021 | 2 | — | 0 | 0 |
| 2022 | 1 | — | 0 | 4 |
| 2023 | 2 | — | 0 | 26 |
| 2024 | 1 | — | 0 | 14 |
| 2025 | 1 | — | 0 | 17 |
| 2026 | 4 | 94 | 0 | — |
What is it indicated for?
StatusFirst TM CHF (Congestive Heart Failure) NT-proBNP is a rapid test for the in-vitro quantitative determination of N-terminal pro-Brain natriuretic peptide (NT-proBNP) in human EDTA plasma. The device is intended for use with the DXpress TM Reader to provide quantitative results as an aid in the diagnosis of CHF.
Indications for use as stated in the FDA summary.
https://510kreport.com/device/K051596 · printed Nov 6, 2026
Cite this page
510(k) Report. “K051596: Statusfirst CHF (Congestive Heart Failure) NT-Probnp, Model 20204.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K051596
Report an extraction error
Are you the manufacturer?
Record history
- FDA decision record loaded May 2, 2026
- Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
- Lineage and recalls computed Nov 3, 2026
- Page last updated Nov 3, 2026